Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin in Untreated Low Tumor Burden Indolent NHL
NCT00414089Phase 2Withdrawn
- Sponsor
- American Health Staffing Group
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in indolent B-cell lymphoma, sponsored by American Health Staffing Group. Status: withdrawn.
02
Drugs
ibritumomab tiuxetan
03
Conditions
indolent B-cell lymphoma
Beyond the preview
Go deeper on NCT00414089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00414089.